The capital is pricing partial cellular reprogramming as the next platform asset in APAC longevity portfolios. The clinical ledger in humans is empty. Altos Labs raised $3 billion in 2022 on the thesis that cyclic expression of Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc -- OSKM) in somatic tissues can reverse epigenetic clock measures without inducing pluripotency, a mechanism that extended median lifespan in progeroid mouse models (Ocampo et al., Cell, 2016) and that has shown epigenetic clock reversal in normally-aged murine tissue at lower effect sizes in subsequent published work. No IND application has been filed with the FDA. No clinical trial notification has been logged with Singapore's Health Sciences Authority under the Health Products Act. No pre-submission consultation is recorded at NMPA's Center for Drug Evaluation. c-Myc is a proto-oncogene; the AAV delivery vectors used in preclinical OSKM protocols share a hepatic-tropism profile with serotypes whose dose-dependent toxicity caused four deaths in Astellas's ASPIRO trial for X-linked myotubular myopathy, a pivotal study halted in 2021. The capital is pricing a mechanism. The mechanism has no human data and a delivery class with a recent mortality record.

Singapore's Economic Development Board committed SGD 25 billion to the Research, Innovation and Enterprise 2025 framework, naming biomedical sciences as a priority vertical; Altos Labs' Singapore Institute is the most visible longevity-capital anchor in that commitment. Altos Labs' scientific leadership cited a five-to-seven year path to human studies from 2022. That timeline ends in 2027. No in-vivo OSKM trial appears at ClinicalTrials.gov. If no clinical trial authorisation is filed at HSA under the Health Products (Clinical Trials) Regulations before 2027 expires, the $3 billion private valuation carries no regulatory anchor at HSA, NMPA's Center for Drug Evaluation, or TGA's Clinical Trial Notification scheme.